Upregulated in CML patients, particularly those in the acute phase, YBX1 cooperates with IGF2BP protein in CML cell lines to regulate the m6A-dependent stability of YWHAZ mRNA, an activator of the PI3K/AKT/mTOR signaling pathway. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.